These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 16539892)

  • 21. Zebrafish: a model for the study of addiction genetics.
    Klee EW; Schneider H; Clark KJ; Cousin MA; Ebbert JO; Hooten WM; Karpyak VM; Warner DO; Ekker SC
    Hum Genet; 2012 Jun; 131(6):977-1008. PubMed ID: 22207143
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The structure of genetic and environmental risk factors for common psychiatric and substance use disorders in men and women.
    Kendler KS; Prescott CA; Myers J; Neale MC
    Arch Gen Psychiatry; 2003 Sep; 60(9):929-37. PubMed ID: 12963675
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The P300 event-related brain potential as a neurobiological endophenotype for substance use disorders: a meta-analytic investigation.
    Euser AS; Arends LR; Evans BE; Greaves-Lord K; Huizink AC; Franken IH
    Neurosci Biobehav Rev; 2012 Jan; 36(1):572-603. PubMed ID: 21964481
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Depression and familial risk for substance dependence: a P300 study of young women.
    Houston RJ; Bauer LO; Hesselbrock VM
    Psychiatry Res; 2003 Sep; 124(1):49-62. PubMed ID: 14511795
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Transcriptional correlates of human substance use.
    Lehrmann E; Freed WJ
    Ann N Y Acad Sci; 2008 Oct; 1139():34-42. PubMed ID: 18991846
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Brain-behavior relationships in externalizing: P3 amplitude reduction reflects deficient inhibitory control.
    Brennan GM; Baskin-Sommers AR
    Behav Brain Res; 2018 Jan; 337():70-79. PubMed ID: 28966148
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association of P3 amplitude to treatment completion in substance dependent individuals.
    Wan L; Baldridge RM; Colby AM; Stanford MS
    Psychiatry Res; 2010 May; 177(1-2):223-7. PubMed ID: 20381882
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Developmental Endophenotypes: Indexing Genetic Risk for Substance Abuse with the P300 Brain Event-Related Potential.
    Iacono WG; Malone SM
    Child Dev Perspect; 2011 Dec; 5(4):239-247. PubMed ID: 22247735
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genes mediate the association between P3 amplitude and externalizing disorders.
    Hicks BM; Bernat E; Malone SM; Iacono WG; Patrick CJ; Krueger RF; McGue M
    Psychophysiology; 2007 Jan; 44(1):98-105. PubMed ID: 17241145
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The utility of neurophysiological markers in the study of alcoholism.
    Porjesz B; Rangaswamy M; Kamarajan C; Jones KA; Padmanabhapillai A; Begleiter H
    Clin Neurophysiol; 2005 May; 116(5):993-1018. PubMed ID: 15826840
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Outcome predictors in substance use disorders.
    Ciraulo DA; Piechniczek-Buczek J; Iscan EN
    Psychiatr Clin North Am; 2003 Jun; 26(2):381-409. PubMed ID: 12778840
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reward Sensitivity of ACC as an Intermediate Phenotype between DRD4-521T and Substance Misuse.
    Baker TE; Stockwell T; Barnes G; Haesevoets R; Holroyd CB
    J Cogn Neurosci; 2016 Mar; 28(3):460-71. PubMed ID: 26601911
    [TBL] [Abstract][Full Text] [Related]  

  • 33. From genotype to EEG endophenotype: a route for post-genomic understanding of complex psychiatric disease?
    de Geus EJ
    Genome Med; 2010 Sep; 2(9):63. PubMed ID: 20828426
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Substance dependence and non-dependence in the Diagnostic and Statistical Manual of Mental Disorders (DSM) and the International Classification of Diseases (ICD): can an identical conceptualization be achieved?
    Saunders JB
    Addiction; 2006 Sep; 101 Suppl 1():48-58. PubMed ID: 16930161
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Behavioral disinhibition and the development of early-onset addiction: common and specific influences.
    Iacono WG; Malone SM; McGue M
    Annu Rev Clin Psychol; 2008; 4():325-48. PubMed ID: 18370620
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diagnosis of comorbid psychiatric disorders in substance users assessed with the Psychiatric Research Interview for Substance and Mental Disorders for DSM-IV.
    Hasin D; Samet S; Nunes E; Meydan J; Matseoane K; Waxman R
    Am J Psychiatry; 2006 Apr; 163(4):689-96. PubMed ID: 16585445
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Curious cases: Altered dose-response relationships in addiction genetics.
    Uhl GR; Drgonova J; Hall FS
    Pharmacol Ther; 2014 Mar; 141(3):335-46. PubMed ID: 24189489
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Computed EEG abnormalities in panic disorder with and without premorbid drug abuse.
    Abraham HD; Duffy FH
    Biol Psychiatry; 1991 Apr; 29(7):687-90. PubMed ID: 2054439
    [No Abstract]   [Full Text] [Related]  

  • 39. Are clinical impressions of adolescent substance use accurate?
    Wilson CR; Sherritt L; Gates E; Knight JR
    Pediatrics; 2004 Nov; 114(5):e536-40. PubMed ID: 15520086
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genetic vulnerability to drug abuse.
    Duaux E; Krebs MO; Loo H; Poirier MF
    Eur Psychiatry; 2000 Mar; 15(2):109-14. PubMed ID: 10881207
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.